Phosphodiester content measured in human liver by in vivo 31P MR spectroscopy at 7 tesla
Authors:
- Lucian A.B. PurvisLPLucian A.B. Purvis
- William T. ClarkeWCWilliam T. Clarke
- Ladislav ValkovičLVLadislav Valkovič
- Christina LevickCLChristina Levick
- Michael PavlidesMPMichael Pavlides
- Eleanor BarnesEBEleanor Barnes
- Jeremy F. CobboldJCJeremy F. Cobbold
- Matthew D. RobsonMRMatthew D. Robson
- Christopher T. RodgersCRChristopher T. Rodgers
Open Access
- 28 February 2017
- journal article
- research article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 78 (6) , 2095-2105
Abstract
Purpose: Phosphorus (31P) metabolites are emerging liver disease biomarkers. Of particular interest are phosphomonoester and phosphodiester (PDE) “peaks” that comprise multiple overlapping resonances in 31P spectra. This study investigates the effect of improved spectral resolution at 7 Tesla (T) on quantifying hepatic metabolites in cirrhosis.Methods: Five volunteers were scanned to determine metabolite T1s. Ten volunteers and 11 patients with liver cirrhosis were scanned at 7T. Liver spectra were acquired in 28 min using a 16‐channel 31P array and 3D chemical shift imaging. Concentrations were calculated using γ‐adenosine‐triphosphate (γ‐ATP) = 2.65 mmol/L wet tissue.Results: T1 means ± standard deviations: phosphatidylcholine 1.05 ± 0.28 s, nicotinamide‐adenine‐dinucleotide (NAD+) 2.0 ± 1.0 s, uridine‐diphosphoglucose (UDPG) 3.3 ± 1.4 s. Concentrations in healthy volunteers: α‐ATP 2.74 ± 0.11 mmol/L wet tissue, inorganic phosphate 2.23 ± 0.20 mmol/L wet tissue, glycerophosphocholine 2.34 ± 0.46 mmol/L wet tissue, glycerophosphoethanolamine 1.50 ± 0.28 mmol/L wet tissue, phosphocholine 1.06 ± 0.16 mmol/L wet tissue, phosphoethanolamine 0.77 ± 0.14 mmol/L wet tissue, NAD+ 2.37 ± 0.14 mmol/L wet tissue, UDPG 2.00 ± 0.22 mmol/L wet tissue, phosphatidylcholine 1.38 ± 0.31 mmol/L wet tissue. Inorganic phosphate and phosphatidylcholine concentrations were significantly lower in patients; glycerophosphoethanolamine concentrations were significantly higher (P < 0.05).Conclusion: We report human in vivo hepatic T1s for phosphatidylcholine, NAD+, and UDPG for the first time at 7T. Our protocol allows high signal‐to‐noise, repeatable measurement of metabolite concentrations in human liver. The splitting of PDE into its constituent peaks at 7T may allow more insight into changes in metabolism. Magn Reson Med 78:2095–2105, 2017. © 2017 The Authors Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Keywords
Funding Information
- Wellcome Trust
- Royal Society (098436/Z/12/Z)
This publication has 62 references indexed in Scilit:
- 31P MRSI and 1H MRS at 7 T: initial results in human breast cancerNMR in Biomedicine, 2011
- Abnormal Hepatic Energy Homeostasis in Type 2 Diabetes†Hepatology, 2009
- Liver biopsy†Hepatology, 2009
- Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experimentNMR in Biomedicine, 2008
- Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis CJournal of Clinical Pathology, 2006
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Standard liver volume in the caucasian populationLiver Transplantation and Surgery, 1999
- Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.Gut, 1996
- Einfluß der Ernährungslage auf das31P-MR-Spektrum der gesunden LeberRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1990
- THE VARIATION OF PATHOLOGICAL CHANGES IN THE LIVER EVALUATED BY DOUBLE BIOPSIESActa Pathologica Microbiologica Scandinavica Section A Pathology, 1979